DOTmed Home MRI Oncology Ultrasound Molecular Imaging X-Ray Cardiology Health IT Business Affairs
News Home Parts & Service Operating Room CT Women's Health Proton Therapy Endoscopy HTMs Pediatrics
SEARCH
Posição atual:
>
>
> This Story

Forward Printable StoryPrint Comment
advertisement

 

advertisement

 

Business Affairs Homepage

Strong exhibitor registration for COMPAMED 2019

MedCrypt announces $5.3 million Series A funding round

PTC Therapeutics and MRI Interventions announce strategic investment

Philips annual general meeting of shareholders re-appoints CEO Frans van Houten and CFO Abhijit Bhattacharya

ZAP Surgical Systems responds to Elekta lawsuit

Varex completes acquisition of Direct Conversion

DrFirst structures a new $17 million commercial financing facility with SunTrust

AngioDynamics announces agreement to sell NAMIC fluid management business to Medline Industries, Inc. for $167.5 million

US Med-Equip acquires Medical Support Products, industry leader in northeast, as demand from hospitals reaches record rate

Philips and Vietnamese Hong Duc General Hospital sign multi-year strategic partnership agreement

Almirall enters into a definitive agreement to divest ThermiGen, its medical device aesthetics business

Press releases may be edited for formatting or style
Celling Biosciences is a biotech company focused on the science, research and development of autologous cellular therapy. They expect with the combination of both businesses to generate value for physicians, patients and their shareholders.

Almirall S.A. (ALM) announced that it has entered into a definitive agreement with Celling Biosciences, based in Austin (Texas), to divest ThermiGen for an undisclosed amount. The transaction is expected to close before or on March 29th, 2019.

Story Continues Below Advertisement

THE (LEADER) IN MEDICAL IMAGING TECHNOLOGY SINCE 1982. SALES-SERVICE-REPAIR

Special-Pricing Available on Medical Displays, Patient Monitors, Recorders, Printers, Media, Ultrasound Machines, and Cameras.This includes Top Brands such as SONY, BARCO, NDS, NEC, LG, EDAN, EIZO, ELO, FSN, PANASONIC, MITSUBISHI, OLYMPUS, & WIDE.



In 2018, Thermi generated $18 MM of net sales and had 94 employees, based in Dallas (Texas). Thermi has an installed base of more than 2,000 users with a strong presence across the U.S.

Peter Guenter, Chief Executive Officer of Almirall S.A., said: “Almirall continues to refocus its business towards medical dermatology. With this divestment, Almirall completes its strategic realignment and puts Thermi business in very good hands to capture the potential of the new Arvati innovative platform”.

Kevin Dunworth, Celling Biosciences CEO, explained: “We are excited about the acquisition announced today and the expansion of our portfolio with ThermiGen’s leading energy-based technology. Acquiring this technology will allow Celling to combine their unique cellular therapy devices with the existing ThermiGen technology to offer physicians a unique scientific approach to treat their patience”.


About Thermi
Thermi, an Almirall Company, is a leading global manufacturer of temperature controlled radiofrequency technology. The company’s flagship product is ThermiRF®, a platform technology that uses temperature as an endpoint for various minimally and non-invasive applications (ThermiTight®, ThermiRase®, ThermiSmooth® Face, ThermiVa®, etc.). Thermi also offers the Thermi250™ device as the newest innovative RF for body. Founded in 2012, Thermi is a US based company with its headquarters in Irving, Texas and R&D in Boston, MA.


About Celling Biosciences
Celling Biosciences is a biotech company focused on the science, research and development of autologous cellular therapy. Celling developed the first system on the market that allows users to regulate and select a desired cell type through a patented collection window and integrated ultra-filtration system. Celling is a transformative leader innovating cellular therapy by integrating excellence in research, medical education, advocacy, and product development.


About Almirall
Almirall is a leading skin-health focused global pharmaceutical company that partners with healthcare professionals, applying Science to provide medical solutions to patients and future generations. Our efforts are focused on fighting against skin health diseases and helping people feel and look their best. We support healthcare professionals by continuous improvement, bringing our innovative solutions where they are needed.

Back to HCB News
  Pages: 1

Business Affairs Homepage


You Must Be Logged In To Post A Comment

Anuncie
Aumente a Sua Perceção da Marca
Leilões + Vendas Privadas
Comece
O mais melhor preço
Comprar Equipamento/Peças
Encontre
O preço o mais baixo
Notícia diária
Leia
A notícia a mais atrasada
Diretório
Browse tudo
DOTmed Usuários
Ética no DOTmed
Veja o nosso
Programa das éticas
O ouro parte o programa do vendedor
Receba PH
Pedidos
Programa do negociante do serviço do ouro
Receba RFP/PS
Pedidos
Fornecedores de Healthcare
Veja tudo
Ferramentas de HCP
Trabalhos/Treinamento
Achado/suficiência
Um trabalho
Parts Hunter +EasyPay
Comece as peças
Citações
Certificado recentemente
Vista recentemente
Usuários certificados
Recentemente Rated
Vista recentemente
Usuários certificados
Central Rental
Equipamento do aluguel
Para menos
Vender Equipamentos/Peças
Comece
A maioria de dinheiro
Preste serviços de manutenção ao Forum dos técnicos
Ajuda do achado
E conselho
Simples RFP
Comece o equipamento
Citações
Mostra de comércio virtual
Serviço do achado
Para o equipamento
O acesso e o uso deste local são sujeitos aos termos e às condições do nosso OBSERVAÇÃO LEGAL & OBSERVAÇÃO DA PRIVACIDADE
Propriedade de e proprietário DOTmeda .com, Inc. Copyright ©2001-2019 DOTmed.com, Inc.
TODOS OS DIREITOS RESERVADOS